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Abstract
Bessac, Bret F., M.S. May, 1998
Title:

Pharmaceutical Sciences

Depression-like Behavioral and Endocrine Effects of Brain
Glucocorticoid Type I Receptors In the Male Rat

Advisor: Craig A. Johnston, Ph . D

.^

Much evidence ties decreased brain glucocorticoid receptors together with
anxiety and clinical depression. There are two known types of glucocorticoid
receptors in the brain, type I (MR) and type II (GR). MR and GR often coexist in
hippocampal and other limbic neurons and often cause different effects within
these neurons, within the brain and in animal behavior. The present study
examined the effects of chronic alterations in the stimulation of brain M R on
depression associated behaviors using an open field test, circadian and 24-hour
locomotor activity and plasma corticosterone (B). Rats were chronically exposed
to an intracerebroventricular infusion of vehicle (propylene glycol), M R agonist
(aldosterone) or MR antagonist (spironolactone) using ALZET mini-osmotic
pumps. Two days following pump placement locomotor activity was monitored for
24 hours in all rats. Spironolactone decreased in total 24-hour activity from pre
treatment control levels and all other treatments, (p<0.01). This effect was most
pronounced during the dark phase of the light cycle. There was no difference
between any of the treatment groups in plasma B concentration determined by
RIA, nor inner nor outer squares entered in the open field test. Intracerebral
infusions decreased open field activity, although this was not correlated with the
treatment. MR were examined using a monoclonal antibody raised to the renal
MR ligand-binding domain and GR were examined using a polyclonal antibody.
GR were observed in both kidney and hippocampal tissues, MR were observed
only in the kidney. This was true for both immunocytochemical and Western blot
analysis.
The results provide evidence that brain MR are linked to locomotor activity, and
potentially depression. Furthermore, evidence was collected to suggest that
hippocampal MR are different from renal MR.
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Chapter 1
Introduction

Almost everyone suffers from depression sometime during their life.
Some people feel this emotional state at an extreme level for a prolonged period
of time, and to such an extent, that they are unable to carry on a normal and
productive life. In the Diagnostic and statistical manual of mental disorders (4th
Edition), the American Psychiatric Association has defined a major depression
episode in an adult as having four or more of the following criteria for most of
every day for at least two weeks, in addition to having a depressed mood or loss
of pleasure or loss of interest: 1) a change in weight or appetite, 2) a change in
sleep,

3)

psychomotor

agitation,

4)

decreased

energy,

5)

feelings

of

worthlessness or excessive guilt, 6) difficulty thinking or concentrating or making
decisions, and 7) recurrent thoughts of death, suicidal ideation, or attempted
suicide.^
Major depression is often associated with an environmental stressor, such
as a death of a loved one, loss of employment, etc. Endogenous stressors and
several diseases with endocrine malfunctions or changes are often associated
with depression. These include diabetes mellitus, Cushing's disease, excessive
glucocorticoid therapy, hypothyroidism, post-partum depression, menopause,
pre-menstrual syndrome, and oral and subcutaneous contraceptive therapy,

1

2
decrease in exposure to sunlight (seasonal affective disorder) /

56789

Depression demonstrates an age and gender-related association.

10

To

examine whether gender differences or any particular age group in the
population suffers a greater incidence of depression, or more precisely, has a
greater incidence of prescribed anti-depressant therapy, a survey of population
eligible for Montana MedicAid in 1995 was performed. The MedicAid data base
allowed for gender and age demographics of the recipients of antidepressants.
Many neurochemical theories for the etiological basis for depression have
been proposed.

However most of these have serious problems in time from

when therapy was first applied, time when neurochemical changes occur, and
time when patient notices a therapeutic benefit.

Medical research of the

pharmacology of antidepressant drugs, physiological parameters of patients with
depression, physiological and behavioral parameters in animal models of
depression and the shared characteristics of endocrine stressors associated
with depression has provided evidence that a chronic decrease in available
brain glucocorticoid type I (MR) or type II receptors (GR), or both, could be
involved in the etiology of depression.
In 1967. Seligman et. al., suggested an animal model for modeling human
depression known as the learned helplessness model.

The methodology of

this model is to chronically expose an animal to a stressor which this animal
cannot escape.

Eventually the animal quits attempting to escape the stressor,

even when this animal is provided with a method of escape from the stressor,
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the animal is incapable of attempting such an escape, while an untreated animal
readily performs the escape/^ Seligman and others have adapted these results
to

clinical

psychological

therapy,

such

as

learned

optimism,

providing

environments and methods for people to have self-control of stressors and
reinterpretation of uncontrollable stressors/^
Learned helplessness animals, as well as depressed humans, have been
shown to exhibit abnormal function of the hypothalamic-pituitary-adrenal (HPA)
axis.

The HPA axis is the primary pathway by which the brain regulates the

secretion of the adrenal glucocorticoids, corticosterone or cortisol (CORT). The
paraventricular

nucleus

of

the

hypothalamus

(PVN)

synthesizes

many

neuropeptides, including corticotrophin-releasing hormone (CRH) and arginine
vasopressin (AVP). These peptides are transported down neuronal axons and
secreted from terminals in the median eminence into the blood of the
hypophyseal portal blood vessels. These vessels carry blood directly from the
median eminence to the anterior pituitary, where the CRH and AVP bind to their
respective receptors on corticotroph cells of the anterior pituitary. The binding of
CRH and AVP to their membrane G-protein receptors induces the corticotrophs
to secrete the hormonal peptide, adrenocorticotropin (ACTH), into the blood.
ACTH travels in the blood from the anterior pituitary to the adrenal gland located
at the top of the kidney, where it binds to ACTH receptors found in the adrenal
cortex and medulla. Here, it stimulates the adrenal gland cells to synthesize and
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secrete steroid hormones including CORT from the cortex and stimulates the
synthesis of catecholamines within the adrenal medulla/^
CO RT (cortisol in humans and corticosterone in rats) is relatively
insoluble in the blood, and so, travels through the blood primarily bound to a
carrier protein, cortisol binding globulin.

However, CORT is soluble in the

cellular non-polar lipid bilayer of the plasma membrane, and thus readily enters
into the cytosol of the cells. Certain cells express one or two of the known types
of receptors for CORT, MR and GR. Both GR and M R share the protein motif of
the steroid receptor superfamily, which includes estrogen, retinoic acid, etc.^^
The receptors in this family bind steroids in the cytosol prompting the steroidreceptor complexes to transfer into the cell nucleus where they bind directly to
specific sequences of DMA.

The steroid-receptor complex binding onto these

DMA response elements can directly affect mRNA transcription, and thereby
affecting protein synthesis.
GR are found thoughout the body and thought to be primarily responsible
for the plethora of actions of CORT in the mammalian body including anti
inflammatory, immunosuppressive, metabolic and tubular functions, as well as
effects on glomerular filtration, muscle catabolism, bone structure, and actions
on many CNS nuclei.

In the brain, GR have been found with highest densities

in cortex layers (II, III & VI), amygdala (central & posterolateral), hippocampus
(CA1, CA2, stratum pyramidalis, dentate gyrus & subfonical organ), bed nucleus
of the stria terminalis (medial, lateral & septohypothalamic), hypothalamus
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(parvocelluar cells of the paraventricular, medial preoptic,

periventricular,

dorsomedial and arcuate nuclei; as well as the tuber cinereum), thalamus
(laterodorsal),

lateral geniculate,

Edinger-Westphal

nucleus,

dorsal

raphe

nucleus and locus coeruleus/^
Brain MR have been found to bind CORT with a much higher affinity than
peripheral MR. In the brain, the MR are found predominantly in the hippocampal
formation with much lesser concentrations in lateral septum, amygdaloid bodies,
olfactory nucleus, cortex layer II, cerebellum and brain stem.^®

The rest of the

brain appears to be relatively devoid of MR. Rat brain MR receptor mRNA are
thought to be identical to the MR mRNA found in the kidney, where aldosterone
and other mineralocorticoids act to increase kidney sodium reabsorption.
Kidney

MR

bind

mineralocorticoids.

such

as

aldosterone

and

deoxy

corticosterone, but not CORT, because the MR have a different ligand bindingsite than GR and are co-localized with the enzyme 11-beta hydroxysteroid
dehydrogenase II (H SD -II).^ HSD-II oxidizes the 11-carbon hydroxyl of CORT.
In physiological conditions, aldosterone forms a hemi-acetyl between the 18aldehyde and the 11-hydroxyl, which protects the 11-hydroxyl substituent.
Deoxycorticosterone does not have an 11-hydroxyl. Therefore, these molecules
maintain binding ability.^^
There has been no evidence of HSD-II in the brain. Therefore brain M R
do bind CORT.^^ In fact, these brain MR have a 10-fold higher affinity for CO RT
than do the GR of the brain.^® The identical DNA of the kidney and hippocampal
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M R implies the proteins are identical.

However, the large difference in CO RT

binding in these two tissues (no binding in the kidney and high affinity binding in
the hippocampus) suggests that the proteins comprising the ligand-binding site
are different.

Splice variants of MR have been identified in the hippocampus

and post-translation modifications are possible.

To test whether the

binding site of both tissue MR are identical a monoclonal antibody specific to the
rat kidney ligand binding site was tested in the kidney and hippocampus by
immunohistochemistry and Western blot.
CORT is secreted in a circadian manner, with a peak in humans in early
morning and a nadir late at night.

It is also secreted in response to stressful

stimuli and 24-hour CO RT levels rise in response to chronic immunological or
environmental stress. Brain MR are thought to be always at least 80% bound by
CORT.

However, the amount of CORT bound to GR is thought to fluctuate

between 5% to 90% bound during a 24 hour day, depending on the CORT
available.
In order to regulate CORT secretion, CORT receptors directly or indirectly
decrease CORT synthesis, as well as the synthesis and secretion of the
hormonal peptides of the HPA axis. GR are thought to be primarily involved in
mediating the feedback inhibition on the HPA axis peptides (ACTH and C R H ).^
27 2 8 29

activation inhibits the expression of CRH mRNA In the PVN and in

the pituitary pro-opiomelanocortin (POMC) peptide mRNA (the pro-peptide of
ACTH).^^ MR in the hippocampus are also thought to be involved with regulating
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the amount of CORT secreted and the basal circadian rhythm of CO RT
secretion, although the neurological or biochemical mechanisms underlying this
are not yet understood.^° Decreases of MR or blocking MR binding in the
hippocampus, and decreases of GR or blocking GR binding in the hypothalamus
(but not GR in the hippocampus) are positively correlated with an increased
activation of the HPA axis, resulting in increased plasma CORT.^^
Patients with diseases which are associated with chronic alterations in
CO RT secretion often exhibit symptoms seen in depression.^

These diseases

include Cushing's disease, Addison's disease, diabetes mellitus, autoimmune
disorders, multiple sclerosis, and exogenous therapy with CO RT analogs.

In

animals, many of these diseases are associated with a decrease in GR and MR
levels.^

^

In animal models with an altered HPA axis activity by disease or

pharmaceuticals, there is often a presence of behaviors associated with human
depression and animal learned helplessness, such as diminished response to a
stressor, feeding, cognitive behavior, adaptive behavior, decreased explorative
behavior and decreased 24-hour locomotor activity.^®
In many people with depression, and in learned helplessness animals, the
peaks and valleys of CORT circadian rhythm are diminished and there is an
overall increase in total daily plasma CORT levels.^^ Also, learned helplessness
animals and depressed people often have a less of decrease in plasma cortisol
or pituitary ACTH in response to dexamethasone (a synthetic glucocorticoid)
administration. ^

^ This diagnostic test is known as the dexamethasone
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suppression test.

In one study, non-suppression of plasma cortisol level by

dexamethasone was noticed in 72% of patients with major depression; 87% of
those with melancholia, 100% of mixed bipolars, but only 33% of those with
mania only.^^
The inability of dexamethasone to decrease plasma CO RT and ACTH
levels and the abnormal CORT circadian rhythm in people with depression
implies the CORT receptors in the brain, pituitary and/or adrenal glands (adrenal
CORT synthesis is regulated by GR) are low or less responsive. Both brain GR
and MR are reduced with chronic immobilization and similar chronic stress
(models of learned helplessness).^® ^®
Dexamethasone non-suppression, loss of CORT circadian rhythm with
chronic CORT hypersecretion, and depressed mood often normalizes after
about ten to fourteen days of antidepressant drug therapy, even though
neurochemical

changes

occur

within

minutes

to

hours.

Historically,

antidepressant drugs were derived from plants, such as Hypericum perforatum
(St. John's Wort) and Erthroxylan Coca sp. (cocaine).

In the early 1950's,

investigations by Zeller, by Crane and by Kline noticed alleviation of depression
with a synthetic drug originally used for treating tuberculosis, isoniazid. In the
late 1940's, Haeflinger and Schindler synthesized imipramine, which Kuhn
characterized in 1958 as having antidepressant actions.

Imipramine led to the

synthesis of other similar molecular tricyclic antidepressant drugs (TCAs).

In

order to remove many of the side effects of TCAs, chemical blockers of the
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presynaptic neuronal reuptake transport systems of serotonin (SSRI) have been
synthesized and used successfully to treat depression.
Antidepressants are not the only biological manipulators successful in
depression treatment. Electroconvulsive shock therapy (ECT) has been used as
a treatment for the immediate resolution of depression.

In seasonal affective

disorder, exposure to intense UV light for about an hour per day is an effective
therapy. Lithium has been successfully prescribed for bipolar disorder.
Isoniazid and extracts of St. John’s Wort inhibit the enzyme monoamine
oxidase (MAO).^"* MAO oxidizes the amine on serotonin and catecholamines,
thereby making these molecules inactive at their receptors.

Inhibitors of MAO

allow serotonin, dopamine and norepinephrine to remain active in the neuronal
synaptic cleft for a greater time and concentration.

The antidepressant TCAs

and cocaine competitively inhibited the neuronal reuptake transport systems for
serotonin and/or catecholamines.

Competitive inhibition refers to the fact that

the drugs directly block the site were catecholamines or serotonin interact.
SSRIs are designed to only inhibit the reuptake of serotonin. Neuronal reuptake
transporters act physiologically to remove neurotransmitters from the neuronal
synaptic cleft by transporting them back into the pre-synaptic neuron. Similar to
MAO, reuptake inhibitors increase the time and concentration of catecholamines
and/or serotonin in the synaptic cleft. All of these drugs result in an increase of
catecholamines and/or serotonin in the neuronal synapse within minutes of
intake.

However, the maximal therapeutic antidepressant benefits are not
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noticed for about 10-14 days, which confounds theories suggesting that only low
synaptic serotonin and/or catecholamines are directly responsible for the onset
of depression.
Drugs

which

reduce

serotonin

secretion

or

catacholamine secretion or synthesis, such as reserpine,
methamphetamine,

5,7-dihydroxytryptamine,

synthesis

and/or

, -methylenedioxy-

3 4

p-chloroamphetamine,

hydroxy-dopamine all decrease hippocampal GR and MR.®® s? se

59

or

6

-

so ei S2

Serotonin within the hippocampus acts to increase GR and MR expression. Both
hippocampal MR and GR levels increase after chronic treatment with SSRIs,
TCAs, MAO inhibitors, lithium, or following ECT in a time course which is similar
to the observed effect of these therapies on human mood.®® ®^ ®® ®® ®^ ®® ®®
These results coupled with HPA axis anomalies of patients with depression
directed our attention toward GR and MR in the etiology of depression.
Acute administration of pharmacological GR antagonists have induced
depression-like animal behaviors.^^ ^ ^

Chronic low GR have been

demonstrated in mice with depression-like behaviors and endocrine parameters.
Antidepressants attenuate the HPA axis hypersecretion and depression-like
behaviors in a mouse model expressing GR mRNA anti-sense.^®
characteristics of these mice,

including hypersecretion of the

dexamethasone non-suppression and

learned

The

HPA axis,

helplessness-like behaviors,

provide evidence that depression may involve a decrease in brain GR levels.^
79 80 81 82
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To directly examine the consequences that a chronic decrease in
available brain MR would have on the HPA axis and depression-like behaviors,
an animal model of chronic low MR has been explored.^ An 18-base end anti
sense to M R was delivered into the third cerebral ventricle of a rat with an
osmotic mini-pump for 7 days.

Changes were examined in hippocampal GR,

MR, MR mRNA, a stress behavioral test, morning (nadir) plasma ACTH and
CORT, and plasma ACTH and CORT after the behavioral test stressor. MR anti
sense treatment did not affect hippocampal GR levels, morning plasma ACTH or
CO RT concentrations nor anxiety-like behavior from the stress test (social
defeat and then an elevated plus-maze). As would be expected, hippocampal
MR levels decreased (21%) and MR mRNA increased from the treatment. There
was a slight but significant increase of plasma ACTH, but not CORT, in response
to the behavioral test in the treated rats.
The MR antisense treatment only produced a 21% decline in hippocampal
MR concentrations. In the present experiments, a similar model was examined
but using continuous administration of a MR antagonist, which theoretically
would provide a greater decrease in the available hippocampal MR.

In this

model six days of constant administration of the MR antagonist, spironolactone,
directly into a cerebral ventricle of a rat by an osmotic mini-pump was used.
Chronic administration of a MR antagonist given centrally should increase basal
plasma CO RT concentration. Plasma CORT, 24-hour locomotor activity (to

12
monitor circadian rhythm), and open field tests (a behavioral test of anxiety)
were all measured in this model.
In another experiment the chronic administration of a M R agonist,
aldosterone was utilized, to determine the effects of chronic M R activation on the
same parameters. An agonist is a drug which binds to the receptor and elicits
the receptor to respond in a manner similar to the endogenous ligand, in this
case the agonist-steroid receptor complex binding onto DNA.

Unlike CORT,

neither aldosterone (nor spironolactone) have a high affinity for GR.^^ Chronic
administration of a MR specific agonist given centrally should decrease basal
CO RT and blunt CORT circadian peak levels. Since MR are always about 80%
bound, increasing the amount of available ligand may not produce noticeable
behavioral/neurochemical effects.
Changes in weight, dexamethasone non-suppression, loss of CO RT
circadian rhythm and high 24-hour CORT in people with depression, and the
higher incidence of depression in people having diseases or hormonal therapies
which are associated with abnormal CORT levels implies that CO RT and it's
receptors may be involved in the etiology of depression.
CO RT

circadian

rhythm,

dexamethasone

The loss of normal

non-suppression,

decreased

hippocampal MR and GR in animal models of learned helplessness, the anxiety
and depression-like behaviors of animals demonstrating decreased brain GR
and the increased animal hippocampal MR and GR seen in animals tested with
TCAs, SSRIs, lithium or ECT in a time course similar to their therapeutic effect,
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provide further evidence that chronic decreases in hippocampal GR is involved
in the etiology of depression. The present experiments examined the behavioral
and hormonal effects of chronic alterations in central MR binding and M R ’s
possible role in the etiology of depression.

C h a p te r 2
M a te ria ls an d M eth o d s
Procedure
Acclimate to cages
-4 Day: 24hr Cage activity
-3 Day: Open field activity
-2 Day: Intra-jugular cannula- leftside
-1 Day: Pre-Treatment Plasma samples at 8:00, 14:00, 18:00
0 Day: Set up osmotic pumps
1 Day: Insert brain cannulae and osmotic pumps
2 Day: Rest from surgery
3 Day: 24hr Cage activity
4 Day: Open field activity/ Intra-Jugular cannula- rightslde
5 Day: Treatment Plasma samples at 8:00, 14:00, 18:00
20:00 PBS perfusion; remove brains; cannula patency assessed

Animals
Forty 250g-300g adult male Spague-Dawley rats were obtained from
Harlan Labs.

They were housed singly in the Pharmacy/Psychology Vivarium,

an AAALAC accredited facility, with rat chow pellets and water ac/ libitum, in
standard environmental conditions (white light on 7:00-19:00 and 23°C +/- 1°C).
Rats were housed and maintained according to guidelines published in NIH
Principles for Use of Animals. Guide for Care and Use of Laboratorv Animals.^
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Materials
Rat chow (Purina), Micro-osmotic pumps and brain infusion kit (Alzet
1007D,

Alza,

spironolactone,

Palo

Alto,

glycine,

CA),

sodium

diaminobenzene,

laurel
triton-X

sulfate,
100,

d-aldosterone,

para formaldehyde,

xylene, peroxidase conjugated rabbit anti-mouse and anti-rabbit antibodies
(Sigma, St. Louis, MO), Tween-20, TRIS base, propylene glycol, sodium
hydroxide pellets (J.T.Baker, Phillipsburg, NJ), #0-80 x 1/8" screws and #56 drill
bits (Small Parts, Miami Lakes, FL), dental cement Fastray powder and liquid
(Harry J.

Bosworth,

Inc.,

Stokie,

IL), 2,2,2-tribromoethanol (TBE)

(Fluka,

Ronkonkoma, NY), silicone plastic (Silastic) tubing and non-reinforced silicone
plastic sheeting 0.25 x 3.25 x 0.03 in. (Konigsberg Instruments, Inc., Pasadena,
CA), 100% silicone aquarium sealant (Dow Corning Corp., Dayton, OH),
cardiovascular 4-0 silk (Ethicon, Inc., Somerville, N. J.), wound clips, 23G1
needles, polyethylene tubing PE50, microscope slides and 5cc, 3cc and Ic c
syringes (Becton Dickinson, Inc., Parsippany, NJ), heparin sodium, sodium
phosphate monobasic, sodium phosphate dibasic, 30% hydrogen peroxide,
microscope cover glass (Fisher, Fair Lawn, NJ), sodium chloride (EM Industries,
Inc., Gibbstown, NJ), T^^corticosterone radioimmunoassay kit (Amersham Life
Science

Inc.,

Arlington

Heights,

IL),

Glucocorticoid

receptor

II

and

mineralocorticoid receptor mouse monoclonal antibodies (Affinity BioReagents,
Golden, CO), biotinylated anti-rabbit antibody. Reagent A and Reagent B
(Vector Laboratories, Burlingame, CA), DPX mountant for microscopy (BDH
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Laboratory Supplies, Poole, England, UK), 8 x 10 wells W HO trays, 5.25%
sodium hypochlorite (Shurfine, Northlake, IL), 10% CAP gel TRIS SDS 8x10cm
(ION

Biomedicals, Aurora.

OH),

15 gauge trochar (Innovative Research,

Rockville, MD), immobllon-P transfer membranes (Millipore, Bedford, MA) were
purchased

commercially.

Reagent A

and

B

(Transduction

Lexington, KY) was a gift from Dr. Charles Eyer.

Laboratories,

Biotinylated anti-mouse

antibody (Vector Laboratories, Burlingame, CA) was a gift from Dr. Diana Lurie.
Protein Assay Dye (Bio-Rad, Hercules,CA) was a gift from Dr. Keith Parker.
Film developer (GBX) and fixative reagents were gifts from Dr. Michael Mlnnlck.

Apparatuses
Stereotaxic apparatus (Kopf, Tunga, CA), a cryostat (HistoStat, ReichertJung, Buffalo, NY), drill (Model 750, Dremel, Racine, W l), submini lever switches
(Radio Shack, Fort Worth, TX), 386 computers (Dell), pipetmans (Gilson,
France), a gamma counter (ICN MIcromedIc Systems, Huntsville, AL), a
centrifuge (J-68, Beckman, Redmond, WA), a -80®C refrigerator (Environmental
Equipment, Cincinnati, OH), a camera (Nikon, Japan), Spectrometer (Bausch &
Laumb),

a

microscope

(Nikon,

Japan),

homogenizer

(Tissue

Tearor),

electrophoresis power supply (ISCO, Lincoln, NE), an electrophoresis transphor
tank, and an electrophoresis gel tank (Hoefer, San Francisco, CA) were used.
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Methods
Intracerebroventricular Cannulation and Pump Implantation:
Surgeries were conducted with the rats under tribromoethanol (TBE)
anesthesia (1ml of a 2.5% solution in saline/ kg body weight).

The methods

were similar to those suggested by Alza.^^ The scalp was shaved and washed
with betadine solution. The animal was then placed in a stereotaxic device (SD),
a 2.5 cm long incision was made to expose the cranium, a periosteal elevator
scraped tissue from the skull.

Blunt-nose scissors were used to make a

subcutaneous tunnel from the scalp incision to the mid-scapular area.

At the

end of the tunnel a pocket was made large enough to house the pump and
permit some pump movement. Two holes were drilled through the skull (one -4
mm posterior (AP) from Bregma, -2mm lateral from midline and one +2 mm AP,
+2 mm lateral). Into these holes small stainless steel screws were placed. The
elevator arm of the SD was altered, so that the end not connected to the SD was
attached to an alligator clip. The placement tab of the brain cannula was clipped
and held in place with the alligator clips. The cannula was connected and glued
with epoxy to 7 cm of catheter tubing (0.69 ID) with 28G needle/syringe filled
with solution at the other end of tubing.
solution.

The brain cannula was filled with

At -1.3 mm AP, a hole was drilled through the skull and the brain

infusion L-shaped cannula was lowered -4.5 mm from dura into the third
ventricle.^^ A bolus of 50 pi was injected into the brain to flush any tissue which
could form a clog and to insure the cannula was patent. The cannula was affixed
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to the skull using dental cement. Once the cement hardened, the tubing on the
osmotic pump was removed and the pump was attached to the catheter tubing of
the brain cannula. Then the osmotic pump was inserted into the subcutaneous
pocket. The placement tab was cut from the top of the cannula and the scalp
wound closed with small wound clips.

Osmotic Pump:
The Alzet mini-osmotic pumps provided the animals with chronic exposure
for seven days to intracerebroventriclular (icv) administration of one of three
treatments: MR antagonist (0.6 mg spironolactone/ 1 ml propylene glycol), M R
agonist (0.05 mg aldosterone/1 ml propylene glycol) or propylene glycol vehicle.
The pumps had a mean pumping rate of 1 pl/hour. Therefore, the drug solution
infusion rates were 600 ng spironolactone/hour or 50 ng aldosterone/hour. The
solutions were carefully injected through the 25-gauge fill tube and into the
osmotic pump.

The clear plastic top of the universal flow moderator was

removed. The flow monitor was attached to a 5 mm piece of tubing with a 28gauge needle/syringe filled with solution at the other end of the tubing. Solution
was pushed into the flow monitor until it was filled with solution. Then the flow
monitor was carefully inserted into the pump.

The pumps were incubated

overnight in 0.9% saline at room temperature to assure activation of the infusion
mechanisms.
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Open Field Activity:
Before and four days after surgery, in the late morning (10:00 to 12:00),
animals were placed In an open field apparatus (an open-top box with 46 cm
walls and a 122 x 122 cm floor, with a 7.6 x 7.6 cm grid pattern on the floor). A
video camera recorded the activity In the field for 10 minutes. The time to Initiate
movement, number of total squares entered and the number of inner squares
versus peripheral squares (three rows along the walls) entered were assessed.
Animals were also monitored for rearing, grooming and defecations. The field
was cleaned with dilute ethanol between each session.

24 Hour Cage Activity:
The apparatuses for locomotor activity measurement were constructed by
the investigator.

Each rat was Individually housed in 42x23 cm opaque plastic

rat cages covered by two 21 x 23 cm wire cage tops. Each cage top contained a
similar quanify of water and food, with both the bottles In the middle of the cage.
Each top, also, held a similar quantity of food. Each cage sat on a fixed round
rod in such an orientation that the two ends of the cage were balanced, like a
scale or teeter-totter with the rod being the fulcrum. Under one end of the cage
was a submini lever switch, so when the rat was on that end of the cage the
switch was closed, but when the rat moved to the other end of the cage, the
cage teetered to that side and the switch was opened. The changes of a switch
from open to closed and from closed to open were quantified for every 15
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minutes for 24 hours through a PC computer interface.®^

Chronic intra-jugular cannula placement:
Prior to surgery, cannulae were made by making a small hole in a 1x2 cm
silastic sheet at 1/3 of the longer length and the middle of the shorter length, as
previously described.®^

A piece of 20 cm silastic tubing (0.02 in. ID) was

threaded through the hole until 5 cm had been threaded through the hole. Then
silicone glue was dabbed to the 1/3 section of the sheet, this glue covered
section was folded onto the middle third of the sheet, covering a portion of the
tubing held tight by binding clips until the glue set.

After the glue dried, the

glued portion of the cannula was trimmed close to the tubing, but the third which
was not glued remained untrimmed. The portion of the tubing below where the
sheet was glued to the tubing was cut to a length of 2.8 cm.
Cannulae were surgically implanted under anesthesia of TBE (1 ml/0.1 kg
BW, of a 2.5% solution in saline) as previously described.

The surgical site

was sterilized with 70% ethanol. An incision was made in the chest to expose
the pectoral muscle and the jugular vein. The prepared cannula was flushed by
a syringe filled with heparin (10 kU/ml) attached at the open end with the long
length of tubing.

The other end was attached to an L-shaped 20-gauge/23-

gauge specially designed needle. ^

The needle was shaped, so that the

attached cannula and needle were inserted into the Jugular vein just superior to
the pectoral muscle and then exited the jugular vein beneath the pectoral
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muscle, consequently exiting through the muscle.

The needle was removed

from the cannula and the cannula was pulled back under the muscle and
carefully guided into the vein. The pressure of the pectoral muscle sealed the
exit hole. The cannula was threaded through the vein into the right atrium of the
heart.

The untrimmed section of the sheet acted like a tab, which allowed the

cannula to be anchored to the pectoral muscle by silk thread suture. A 15 gauge
trochar was pushed subcutaneously from the middle of the back of the neck to
the wound site. The syringe was removed and the exposed end of the silastic
cannula was threaded into and through the trochar. The trochar was removed,
leaving the cannula, which exited the back of the neck.

The open end of the

cannula was cut so that a 5 cm portion was exposed and sealed with a knot
under pressure with heparinized saline.

Blood Retrieval:
The animals were individually housed in opaque cages with stainless
steel tops. At least one hour prior to sampling, the knot closing the cannula was
cut.

A 0.75 m PE 50 tube filled with 100 U Heparin/ 1 ml 0.9% saline was

connected to the cannula by a - 5 cm stainless steel tube (28 gauge). The PE
50 tubing connecting tube was strung to the outside of the cage, where it was
attached to a another 0.25m piece of PE 50 tubing by "~5 cm stainless steel tube
(28 gauge). The open end of the 0.25m PE 50 tubing was connected to a 3 cc
syringe containing at least 1 cc of the heparin/ saline.

Plasma samples were
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retrieved by drawing blood up the 75 cm PE 50 tubing and into about a third of
the 0.25 PE 50 tubing by the 3 cc syringe. The 75 cm and 25 cm PE 50 tubing
were detached and a 1 cc heparinized syringe with a 28 gauge needle was
attached to the open end of 0.75m PE 50 tubing and 0.7 ml of blood was slowly
drawn into the heparinized syringe without disturbing the animal.

The two

pieces of PE 50 tubing were reattached and the blood flushed back into the
animal with heparin/ saline (100 U/ml).

Blood samples were removed at 9:00,

14:00 and 18:00 hours, before treatment and after 5 days of treatment. Plasma
was separated by centrifuge at 15,000 rpm and stored at -80**C for hormone
analysis.

Plasma Corticosterone Radio immunoassay:
Plasma corticosterone (B) was measured using the protocol of the
corticosterone radioimmunoassay kit.^^ Plasma samples were placed in a water
bath at 60^C for 30 minutes to displace B from cortisol binding globulin.

One

hundred microliters of each plasma sample was diluted with 400 fil 0.02M borate
buffer pH 7.4 with 0.1% sodium azide in a polystyrene tube.
Standards were prepared by pipetting 500 pi of buffer into 18 polystyrene
tubes. Five hundred microliters of a standard of 400 ng B/ml buffer was pipetted
into two of the tubes and vortexed.

Five hundred microliters of the contents of

these two tubes was transferred into two other tubes and this double dilution was
repeated successively with the remaining tubes giving rise to 2 sets of tubes with
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9 different concentrations of B.

Aliquots of 100 (xl from each of the serial

dilutions were pipetted into 2 sets of 9 tubes with respective dillutlons equivalent
to 0.78, 0.156, 0.312, 0.625, 1.25, 2.5, 5, 10, and 20 ng/ml.
In addition to the labeled standard and sample tubes, 3 tubes were
labeled TC for total counts, 3 tubes were labeled NSB for non-specific binding,
and 5 tubes were labeled Bo for zero binding standard. Two hundred microliters
of buffer was pipetted into the NSB tubes and 0.1 ml of buffer was pipetted into
the Bo tubes. One hundred microliters of rabbit anti-B (400 ng/ml) was pipetted
into all tubes except for NSB and TC tubes. One hundred microliters of [^^^l]B
(approximately 11,570 cpm) was pipetted into all of the tubes.

Then the TC

tubes were removed for counting. All other tubes were vortexed, covered and
incubated for two hours at 22®C. After the incubation, 0.4 ml of the Amerlex-M
goat anti-rabbit second antibody was pipetted into each tube except TC tubes.
All tubes except the TC tubes were then centrifuged for 10-20 minutes at 3000
rpm, 4^C. These tubes’ supernate was aspirated off from leaving a precipitate.
A gamma counter was connected to a computer with Isodata software, a
protocol was written for a log-logit standard curve; the counts per minute of
sample binding minus non-specific binding divided by maximum binding (Bo)
standard minus non-specific binding times 100, versus an X-axis: log dose B
concentration (ng/ml).

The gamma counter read the radioactive counts per

minute of the standards, NSB, Bo and TC and provided this information to the
computer, which provided a standard curve. (See Figure 7, page 45) By applying
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this curve to the unknown samples’ counts per minute minus NSB an estimate of
B concentration in ng/ml could be estimated for each sample. All plasma B was
measured in the same assay, interassay coeffient of varation=0.02, 50%
effective dose=2.5 ng B/ml and sensitivity=0.16 ng B/tube

Brain and Kidney Removal:
In order to remove blood cells from brain and kidney samples for western
blot analysis or immunohistochemical analysis (ICC), the rats were given TBE
anesthesia and transaortically perfused with 0.1M phosphate buffer saline
(PBS), pH 7.4 for 5 minutes. Chest hair was scalped off exhibiting subcutaneous
tissue, an incision was made at the xyphoid process and with a hemostat the
xyphoid process was pulled through the incision. This separates the peritoneal
muscle wall from the vital organs, allowing an incision to be made all along the
diaphragm base of the rib cage. The diaphragm was cut from the ribs, without
damaging vital organs.
parallel to, the sternum.

Two cuts were made 2-3 inches to the side of, and
The hemostat clamped to the xyphoid process was

pulled to the head of the animal and pericardial tissue was cut from the sternum.
This surgery was performed on a refrigerator rack mounted over a sink.
Above the sink sat two 10 gallon barrels containing 5% para-formaldehyde
(RFA) or PBS. A 3 foot piece of 1/4 inch x 1/16 inch class VI plastic tubing was
attached by an adapter to the spigot of each of the barrels.

The tubes were

connected together by a Y glass adapter, which had 2 foot tube on the third arm.
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Each tube had a clamp near it’s end. The last tube had a dull-end 13G needle
attached at the end.
Both the spigots were open and the clamps on the PBS tube and the third
tube were opened to clear out the tubes with PBS.

Then the third tube was

clamped closed and the needle was inserted into the left cardiac ventricle and
threaded up the aorta.

The third tube was undamped again and PBS flowed

into the animal. The right cardiac atrium was cut to allow the PBS/blood to exit.
When the blood had been replaced by PBS. the liver and eyes turned white and
the exiting fluid became clear.

If the tissues were to be analyzed by western

blot, the needle was then removed. The kidneys and brain were retrieved. The
cerebral cortex was pealed off and cut from the corpus callosum of the freshly
retrieved brain. The cerebellum was also removed. The different brain sections
were then frozen at -80®C.
If the tissues were to be analyzed by ICC. the PFA tube clamp was
opened and the PBS clamp was closed.

PFA flowed into the rat for about 5 min.

causing the muscles of the rat to constrict and the limbs to curl. The brain and
kidneys were retrieved and post-fixed in PFA for 4 hours, followed by
cryoprotection in 30% sucrose in PBS until the tissues sunk (about 2 days).

Immunohistochemistry (ICC) of Brain and Kidney M R and GR:
The cerebellum was removed with a straight-edge razor blade. The
different brain sections were then frozen at -80°C. A razor blade was used to
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make coronal cuts just caudal to the mamallary bodies and just rostai to the optic
chiasm. The restai and caudal sections were discarded.
A room temperature cryostatic chuck had tissue freezing medium placed
on top of it, so that all the indented grooves, except the outer most groove were
coated with medium. The caudal end of the middle section of frozen brain tissue
was placed in the freezing medium on top of the chuck. The chuck stem was
placed in a pre-bore hole rn the dry ice, so that the brain platform sat flat on dry
ice.

The brain dorsal and ventral sides were maintained perpendicular to the

chuck platform with cold forceps. Once the medium solidified, the chuck/brain
was placed in the cold (-12*"C) cryostat.

The brain was trimmed to the optic

chiasm (Bregma) using the microtome blade.

At about -2.0 mm AP from

Bregma, the hippocampal folds began to appear.

From this point to the

hippocampal fissure, 40 ^m coronal sections were obtained.
The 40 pm coronal sections were placed in 0.01 M PBS filled W H O tray
wells with a #2 round artificial horsehair paintbrush. After five minutes, sections
were moved from one well of PBS to another.

Endogenous peroxidase activity

was removed by immersion of the sections for 10 minutes in hydrogen peroxide
(500 pi 30% H2 O 2 in 30 ml PBS) filled wells followed by two 5 minute washes in
PBS wells. Sections were blocked with normal goat serum (NGS) in wells filled
with 200 pi N G S /10 ml D aylB (0.5 g bovine serum albumin/ 50 ml P B S /150 pi
Triton-X).

After one hour, the sections were placed in wells containing rabbit

polyclonal antibody to GR (Dilution 5pg/ml D aylB ) or mouse monoclonal
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antibody to M R in D aylB (Dilution 1:100).®^
Microscope slides were placed in a slide tray. One gram gelatin and 0.5g
chromic potassium sulfate was dissolved in 1000 ml flask containing 500 ml
distilled water and gently heated until mostly dissolved.

The insoluble gelatin

was then filtered out. The slides were immersed in a glass tray containing 0.1%
acid 70% alcohol (290 ml distilled water + 1 ml HCI + 700 ml absolute methanol)
for two minutes, followed by two minutes in a glass tray with distilled water. The
slides were then placed for two minutes in gelatin subbing solution and stored
overnight in an oven at 37°C.
The next day, the sections received two 5 minute washings in wells
containing Day2B (20 ml D aylB + 40 ml PBS). The sections were then placed in
wells of biotin conjugated goat anti-rabbit or horse anti-mouse secondary
antibody in Day2B (Dilution 1:1000).

One half hour after the application of

antibody, a solution to express the biotin made of 50 pi reagent A, 50 pi reagent
B and 20 ml Day2B (A+B) was made. One hour after immersion in secondary
antibody, the sections received two 5 minute washings in wells containing
Day2B, followed by immersion in wells of A+B. One hour after the application of
A+B, the sections received two 5 minute washings in PBS.
Sections were developed using the chromagen, diamino benzene diluted
20 mg in 15 ml PBS (DAB+B). The sections were immersed in 1 ml DAB+B +
19 ml PBS + 6.6 pi 30% H2 O 2 until sections turn a suntan brown.

DAB

contaminated material other than the sections and the DAB solution were placed
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in 5.25% sodium hypochlorite to destroy the carcinogenic DAB.
The developed sections were placed in a petrl dish filled 3/4 full with PBS
and mounted onto gelatin coated microscope slides with the paintbrush.

The

slides were air dried, then dehydrated for coverslipping using a series of
immersions in increasing concentrations of ethanol. First, slides were immersed
for 5 minutes in 70% ethanol, followed by 5 minutes in 95% ethanol, followed by
two 5 minute immersions in 100% ethanol and finally two 5 minute immersions in
xylene. The slides then had DPX mountant applied and a coversiip was secured
by the DPX. The coverslipped slides dried for 12 hours.
The slides were examined with a Nikon microscope at lOx, 40x and 50x
powers and photos taken with an attached camera.

SDS Gel Electrophoretic Western ImmunoBlot of Brain and Kidney M R and GR:
The frozen sections were removed from the refrigerator. A razor blade
was used to make coronal cuts just caudal to the mamallary bodies and just
rostai to the optic chiasm.

A room temperature cryostat chuck had tissue

freezing medium placed on top of it, so that all the indented grooves, except the
outer most groove were coated with medium.

The caudal end of the middle

section of brain tissue was placed in the freezing medium atop the chuck. The
chuck stem was placed in a pre-bore hole into dry ice, so that the brain platform
sat flat on dry ice. Once the medium solidified, the chuck/brain was placed in
the cryostat. The brain was trimmed to the optic chiasm (Bregma). At about -2.0
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mm AP from Bregma, the hippocampal folds began to appear. A cut was made
with a razor blade separating the hippocampus and the hypothalamus from this
point to the end of the section. The hippocampus was stored at -80*'C in pre
weighed vials on dry ice for Western blot analysis.
The hippocampal and kidney tissues were weighed and 5 ml TRIS buffer/
gram tissue sample (200g/l) was added into the vials.

The tissues were

homogenized until completely homogenous to the eye.

A Bradford protein

analysis was conducted on each tissue sample.

Samples of 10-300 \xg! well

were used for Western blot analysis. This amount of protein was pipetted from
the homogenized sample into an eppendorf tube and q.s. to 40 pi with (6x
buffer). A pin hole was placed into the top of each tube.
A

CAPS

pre-poured

gel

(Amersham)

was

placed

onto

the

gel

electrophoretic unit (GEU) with the shorter gel glass plate facing towards the
electrodes and forming a seal with rubber gasket.^^ The gel plates were clipped
onto the GEU.

A 1 ml glass pipette washed the gel by pouring tank buffer

(9.075g TRIS, 43.2 g glycine, 3g sodium laurel sulfate in 3L de-ionized water) on
top of wells. The inner holding area (behind the gel) was loaded with tank buffer
until level with the top of the shorter glass plates. The seal between the glass
plate and the gasket was examined for any leaks.

If no leaks were observed

then the lower holding area was filled with tank buffer.
The tissue sample/ 6x buffer tubes were put into a styrofoam float and
placed in boiling water for 150 seconds.

The bottom half of the tubes were
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exposed in the water. Into the first gel well 30 \i\ stained protein standard was
pipetted with a capillary pipette tip.

The rest of the wells had the samples/6x

pipetted into them.
The electrophoretic power supply had it's parameter's set; meter scale:
volts, current: 100 mA on 600 V, voltage limit: max., wattage limit: max., current
limit: 20. The EGU top was connected with the EGU and the power supply. The
EGU water cooling system and the power supply were turned on.
When the samples' dye had migrated to bottom of the gel, a membrane
was placed in 100% methanol and the transphor electrophoretic unit (TEU) was
filled with transphor buffer (20% methanol in tank buffer) to the start fill level, the
power supply was turned off and the gel was removed. The gel was removed
from the glass plates and gently placed in transphor buffer. A gel sandwich was
made in transphor buffer; black side down, sponge, 2 pieces of paper, gel,
membrane, 2 pieces of paper, sponge, gray side. The sandwich was transferred
into the TEU with black side facing black electrode end and the TEU was filled to
minimum buffer level with transphor buffer.

The TEU and power supply were

moved to a cold room and the power supply had it's parameters set; wattage
limit: max., current limit: max., voltage limit: 20. The TEU was placed on a stir
plate and a stir bar was spun in the TEU. The power supply was turned on and
the proteins in the gel transferred into the membrane overnight.®®
The next day, the membrane was removed and air dried.

If the stained

protein standard was noticed on the membrane, the transphor was considered
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successful. The dry membrane was soaked in a blocking solution of (TTBS) with
5% non-fat milk for an hour. This was followed by placing the membrane in fresh
TTBS + 5% non-fat milk and a mouse monoclonal M R antibody (Dilution 1:250)
or a rabbit polyclonal GR antibody (Dilution Ip g /lm l) overnight at 4°C. The next
day the membrane was washed by soaking it in fresh TTBS every 5 minutes for
30 minutes, then in TTBS + 5% non-fat milk and horseradish peroxidase
conjugated secondary anti-body, anti-mouse (1:4000) or anti-rabbit (1:8000) for
an hour. The membrane was then washed as previously described.
In order to detect and quantify the target protein on a permanent media,
the membrane was soaked in luminol based chemiluminescent reagents for 2-10
minutes.

Under a red light, the membrane was sandwiched between plastic

wrap and had electro-chemiluminescent film placed on top of it for 10 seconds to
5 minutes. The film was developed in GBX developer for 5 minutes, washed for
a minute in running tap water and fixed for 5 minutes.

If the target protein, MR

or GR, was present, the film had a black band from the luminescence of the
peroxidase on the secondary antibody.

Bradford Protein Analysis
A standard curve of pure protein concentration was created with bovine
serum albumin (BSA).

First, 25 mg BSA were mixed in 10 ml of TRIS buffer,

which is a concentration of 2.5 mg/ml. 0.1 ml of the standard of 0.25 mg/ml was
pipetted into two of the tubes containing 0.9 ml buffer and vortexed.

0.5 ml of
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the contents of these two tubes was transferred into the two tubes with 0.5 ml
buffer and this dilution was repeated successively with the remaining tubes
giving rise to 2 sets of tubes with 6 different concentrations of BSA. Aliquots of
0.1 ml from each of the serial dilutions were pipetted into 2 sets of 6 tubes.
Next, 0.7 ml buffer were pipetted in each of the appropriately labeled polystyrene
tubes, followed by 0.2 ml of Bradford Reagent and vortexing each of the
respective dilutions of 0.78, 1.56, 3.12, 6.25, 12.5, and 25 pg/ml.^^ Three blank
tubes were made with 0.8 ml buffer + 0.2 ml Reagent.
A spectrometer was set at wavelength of 595 nm and zeroed with distilled
water. The absorbance of the blank tubes was read versus the distilled water
and then the fluid of the blanks was combined together.

The combined blank

fluid was placed in the reference beam cuvette and the absorbance of each of
the samples containing tissue was found.

The absorbance was compared to

previous experiments using BSA.
A standard curve was then made for the tissue sample to find how the
slope of absorbance of a tissue sample versus the of concentration of the tissue
compared to the BSA protein analysis slope.

This comparison provided an

estimation of protein concentration in the sample.

Twelve labeled tubes were

used, the first three contained 0.8 ml TRIS buffer, the next three tubes contained
800 pi buffer + Ip l homogenized tissue, the next three tubes, 800 pi buffer + 2 pi
tissue and the final tubes, 800 ml buffer + 4pl tissue. The rest of the procedure
was identical to that described above. (See Figure 11, page 49)

33
Statisticai Analysis:
Between-within split plot analysis of variance and multiple comparison
procedure in a Bonfronni recognition procedure were computed with SPSS
software available available through the University of Montana mainframe
c o m p u te r.D u n n e tt's test for comparison to a control baseline were computed
with Minitab software also available through the mainframe.^^

The p<0.05

was used as a minimum criterion of significance in all experiments.

Montana MedicAid Population Survey:
Montana MedicAid is a state program to help low income Montanas pay
for medical bills.

The supervising officers, Mr. Jeff Ireland and Ms. Dorothy

Paulson, provided the 1995 anonymous data with a software package.

Chapter 3
Results
24~Hour Activity:

On each test day, at least one rat from each treatment group was represented.
Prior to treatment and after three days of intracerebral Alzet mini-pumps, the
total 24-hour activity (indicated by total cage switch closures) of each animal
was recorded.

To remove the error associated with cage differences, each

treatment activity was subtracted from baseline cage activity (average of all pre
treatment recordings of the cage apparatus that measured the treatment rat's
activity). The rats receiving spironolactone displayed a significant decrease in
total 24-hour activity.

Rats receiving aldosterone or vehicle did not show any

significant difference in total 24-hour activity from baseline cage activity, and
were not significantly different from each other.

Rats are nocturnal animals, and

the difference in cage activity was noticed primarily during dark (active) hours
(See Figure 1 and Table 1). There was very little cage activity by the rats in any
treatment group during the “lights on” period (See Figure 2 & Table 2).

The

ability of spironolactone to decrease activity supports the hypothesis that brain
M R are involved, at least in part, for behaviors indicative of depression.

That

continuous agonist treatment did not alter activity may not be surprising as more
than 80% of brain MR are thought to be bound even in the absence of the
exogenous agonist treatment.
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Daily Activity: Tx minus PreTx Baseline of Cage Appartus
150

□ Vehicle(6)
Aldosterone(6)
D Spironolactone(6)

Total

Figure

Lights Out

1: Total 24-hour activity: Treatm ent minus

Lights On

Baseline o f Cage

Apparatus. Height of each bar represents the mean total activity per time period
for all rats within each treatment group with baseline cage activity subtracted,
and the vertical lines represent the SEM obtained from n=6 animals per group. *,
significantly different p<0.05.
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T ab le 1: Analysis o f Variance 24-hour activity: Treatm ent m inus Baseline o f
C age Apparatus. Split plot analysis of variance examined difference in activity
over time, activity of treatments for the sum of all the times, as well as an
interaction of activity of treatments and time.

There is a significant difference in

activity depending on the time of day and total activity for 24-hours between the
treatment groups.
Source
Treatment Groups
Rats Nested Within Groups
Hours
Treatment Groups X Hrs
Rats Nested Within Groups X Hrs
Total

DF
2
15
23
46
345
431

S3
11901
9985
15793
27427
119308
1184415

MS
5950
666
687
596
346

F
8.94

P
0.003

1.99
1.72

0.005
0.004

Hourly Activity: Tx minus PreTx Cage Error
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Figure 2: Hourly Activity: Net change in activity measured as the difference
between pre-treatment and treatment cage movements at hourly intervals over a
24-hour day in n=G animals per group. Lights are on from 7:00 to 19:00 hour.
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T ab le 2: Analysis o f Variance Hourly Activity; Treatm ent m inus Baseline o f
Cage Apparatus. Multiple comparison procedure examined differences between
treatment groups at each time in a Bonfonni correction procedure nested on a
pooled error term which is rats within treatment groups. #, significance p<0.05.
DARK Hrs
Spir X Aldo
SpirXVeh
Aldo X Veh
LIGHT Hrs
Spir X Aldo
SpirXVeh
Aldo X Veh

8PM 9 10
11 12AM
1
2
3
4
5
6
7
#
# # .
#
.....................................................
#
# #
^
^
8AM 9 10
11 12PM
1
2
3
4
5
6
7
.....................................................
-.................................................................................................................
...........................................................

Open Field Test:
Open field behavior was measured by counting squares entered (inner,
outer and total) by each animal in a 10 minute period.

Time of initiation of

movement out of primary squares was also observed.

All of the treatment

groups demonstrated a decrease in the total, inner and outer squares entered
compared to pre-treatment values, implying icv surgery and recovery caused
anxiety in animals. The treatment groups did not significantly differ from each
other in the total, inner or outer squares entered.(See Figure 3, 4 and 5, and
Table 2)

These open field tests were conducted in the morning when no

difference in 24-hour activity levels were observed in the cage activity between
the treatment groups. It is not known whether analysis of open field behavior in
dark (active) period would have provided different results.
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Open Field Test: Total Squares Entered

I
%

PRE

VEHICLE

ALDO

Figure 3: Open Field Test Total Squares Entered.

SPIRO

Height of each bar

represents the mean total squares entered for all rats within each treatment
group (ALDO=aldosterone, SPIRO=spironolactone, SHAM=vehicle) and prior to
treatment (PRE).

The vertical lines represent the SEM. N=6

animals per

treatment group, n=18 PRE animals. *, significantly different p<0.05 from PRE.
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Open Field Test; Outer Squares Entered

PRE

VEHICLE

ALDO

SPIRO

Figure 4: Open Field T est Outer Squares Entered. Height of each bar
represents the mean outer squares entered for all rats within each treatment
group (ALDO=aldosterone, SPIRO=spironolactone, SHAM=vehicle) and prior to
treatment (PRE).

The vertical lines represent the SEM. n=6

animals per

treatment group, n=18 PRE animals, *, p<0.05 , significantly different from PRE.
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Open Field Test: Inner Squares Entered
e 60

S 40

T_
PRE

VEHICLE

ALDO

SPIRO

Figure 5: Open Field Test Inner Squares Entered. Height of each bar
represents the mean Inner squares entered for all rats within each treatment
group (ALDO=aldosterone,

SPIRO=spironolactone) and

prior to treatment

(P R E )T h e vertical lines represent the SEM, n=6 animals per treatment group,
n=18 PRE animals.
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T ab le 3: Open Field T est (a) Inner Squares (b) Open Squares and (c) Total
Squares. Dunnett's test for comparison to a control baseline for an approximate
analysis between baseline (PRE) and treatment rats was examined. It is
approximate because PRE rats are distributed 6 at a time into treatment groups
(but a conservative approximation because error was larger than it would be in
the fully appropriate analysis).

Total and outer squares entered by PRE were

significantly different from treatment.
(a)lnner Squares Source
Treatment Groups
Animals Nested Within Groups
Total
(b)Total Squares Source
Treatment Groups
Animals Nested Within Groups
Hours

DF
3
32
35
DF
3
32
35

SS
9877
44278
54155
SS
1619684
1518591
3138274

MS
3292
1384

F
2.38

p
0.088

MS
539895
47456

F
11.38

p
0.000

Plasma Corticosterone Levels:
Plasma CO RT levels demonstrated no differences between treatment
groups at any time point examined. The mean of the first bleed (9AM, PRE) of
plasma CORT was significantly higher than of the other plasma samples. (Table
5) This may have indicated that basal levels of CO RT had not been reached by
the time of the first sampling from the change in environment.

However, the

levels fluctuated greatly between bleed times for an individual rat and between
rats bled at the same time within the same group. The mean of minimal CO RT
value was in the range of 50-100 pg/ml, which also indicates a stress effect. The
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level of CO RT was elevated in rats even at times expected to show a nadir in
C O R T secretion (Figure 6 and Table 4 & 5). These results imply that plasma
C O R T levels were somewhat elevated at all times examined and in all treatment
groups.

This effect was seen even considering that handling was minimized

during the experiment. The fact animals had blood drawn in a room other than
their usual housing and animals had less than one day to recover from the intrajugular venous cannulatron surgery may have contributed to elevated CORT
levels observed, although previous experiments using this technique have
demonstrated a minimal effect of this minor surgery the previous day.^°^
The lack of any difference of plasma CORT between any of the treatment
groups was unexpected as acute studies have demonstrated changes in plasma
CO RT following acute administration of an icv MR agonist or M R antagonist.
However, another chronic study manipulating brain MR with continuous infusion
of M R antisense demonstrated no effect on CORT.
It was very difficult to obtain a plasma sample during the nocturnal hours
from rats under red light because of the high activity of the rats at this time and
the difficulty in seeing the blood.

When obtained, often some manipulation of

the animals had to be performed introducing a potential for stress. The ability to
remove stress free dark hours blood samples would have been beneficial, since
CO RT plasma levels fluctuate in a circadian rhythm with higher levels occurring
during dark hours, and the theory being tested in this research was that MR are
involved in the regulation of this circadian rhythm of CORT.

43
Plasma Corticosterone
PRE(14)
□ Vehicle(G)
BAIdosterone(6)
D Spironolactone(6)
o) 200

K 150

9AM

2PM

6PM

MIN

Figure 6: Plasma Corticosterone Levels at 9:00 (9AM), 14:00 (2P M ),18:00
(6PM), and the low est sam ple (MIN). Height of each bar represents the mean
plasma CO RT [pg/ml] for all rats within each treatment group and prior to
treatment (PRE) at 9:00,

14:00 and

18:00 hours; and the lowest value

obtained/animal (MIN). The vertical lines represent the SEM. N=6 animals per
treatment group, n=12 PRE animals. *, significantly different p<0.05.
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T ab le 4; Analysis o f Variance Corticosterone Levels o f Treatm ent and PreTreatm ent Anim als. A Dunnett's test for comparison to a control baseline (pre
treatment) was calculated for an approximate analysis between baseline and
treatment animals for each time point and minimum corticosterone sample. It is
approximate because the rats in baseline are distributed 6 at a time into the
treatment groups and the not all the treatment animals matched up with a pre
treatment measure (n=12) (but it is a conservative approximation because error
was larger than it would be in the fully appropriate analysis).

There was

significantly higher CORT at 9AM of PRE versus treatment groups at 9AM.
MIN Plasma CORT, PreTx & Tx
Treatment and Pre Tx Groups
Animals Nested Within Groups
Hours
9AM CORT, PreTx & Tx
Treatment and Pre Tx Groups
Animals Nested Within Groups
Hours
2PM Plasma CORT, PreTx & Tx
Treatment and Pre Tx Groups
Animals Nested Within Groups
Hours
6PM Plasma CORT, PreTx & Tx
Treatment and Pre Tx Groups
Animals Nested Within Groups
Hours

DF
3
23
26
DF
3
23
26
DF
3
23
26
DF
3
23
26

SS
29074
101212
130286
SS
89895
203122
293016
SS
20382
505037
525420
SS
52791
189068
241859

MS
9691
4401

F
2.20

MS
29965
8831

F
3.39

MS
6794
21958

F
0.31

P
0.818

MS
17597
8220

F
2.14

P
0.123

P
0.115

P
0.035

T ab le 5: Analysis o f Variance o f Corticosterone Levels o f Treatm ent
Anim als. Between-within split plot analysis of variance examined difference of
plasma CORT between treatment groups over time of day, the main effects of
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treatment and time of day, as well as an interaction of treatment and time of day.
There was no significant difference in plasma CO RT depending on the time of
day or plasma CO RT between treatment groups by time of day or between total
C O R T of the treatment groups.
Plasma CORT Source
Treatment Groups
Rats Nested Within Groups
Time of Day
Treatment Groups X Time of Day
Rats Nested Within Groups X Time
Total

DF
2
15
2
4
30
53
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Figure 7: Standard Curve o f Plasma CORT for RIA.
The percentage of gamma counts per minute (cpm) for known quantities of
CO RT (B) are calculated from the absence of CO RT (BO), cpm of non-specific
binding of secondary antibody (NB) is subtracted from both B and BO.
are compared in a logit versus log graph against the ng quantity of CORT.

These

46
Cannutae Patency:
Immediately, after animals were sacrificed, the cannulae were tested for
patency and by six days the cannula of several animals were not patent.

In

studies performed after the experiment it was demonstrated that most cannulae
would have remained patent for 3-4 days even with the vehicle and flow
parameters used.

Western Biot o f Kidney and Hippocampal M R and GR:
The positive binding of kidney MR and the lack of antibody binding in the
hippocampus could be interpeted that the kidney and hippocampal M R are not
identical proteins. The dénaturation of Western blots would remove ligands from
protecting

the

MR

antibody

binding

site.

Several

concentrations

and

purifications of MR and MR antibody yielded identical results. The positive GR
antibody binding in both hippocampal and kidney, demonstrates GR presence in
both hippocampal and renal tissues.
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K IO k iK S O

K100 ; IK 200

H50

H200

H lO

H100

a)

HI

K

b)
Figure 8: MR and G R W estern Blots o f Kidney and Hippocam pus.
a.)The black bands are from the chemoluminescence of M R monoclonal
antibody binding of kidney tissues at 200|xg (positive control), 10pg, 50pg,
100pg and 200pg total denatured protein/well (+C, K10, K50, K100, K200). To
the left of each kidney sample an equal concentration of hippocampal tissue was
placed, except for +C (H10, H50, H100, H200).
b,)The black bands are from the chemoluminescence of GR antibody binding of
renal (K) and hippocampal (HI) tissues at 200pg total denatured protein/well.
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Immunocytochemistry (ICC) of Kidney and Hippocampal MR and GR:
The similarity of ICC results with Western blot results further strengthen
the observation that the kidney and hippocampal M R appear to be unidentical
proteins.

However, hippocampal MR are thought to be substantially ligand

bound, which could mask the MR antibody binding site.

S .

♦

a.)M R in kidney

V

^

b.)G R in kidney

Figure 9: MR and G R ICC o f Renal Tissue (20x M agnification).
a.) The stained cells are M R monoclonal antibody binding MR in kidney tissue.
b.) The stained cells demonstrate GR antibody binding in kidney.
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a.)M R in hippocampus

b.)G R in hippocampus

Figure 10: MR and G R ICC o f Hippocampal Tissue (20x M agnification).
a.) This figure shows a lack of MR antibody binding in hippocampal dentate
gyrus tissue.
b.) The arrows in this figure point to stained cells in hippocampal dentate gyrus
tissue binding GR.
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1995 Survey of Montana MedicAid Antidepressant Recipients:
There were three to four times more women recipients of antidepressants
than men for any adult age group. Women in their child bearing years were by
far the largest number of recipients of antidepressant drugs.
25%

Percent Anttdepressant Recipients
Total

20%

□ Female
□ Male

15%

10%

5%

0%
Total

Figure

11:

Percent

0to20

of

1996

65+

21to64

Montana

Medic Aid

recipients

receiving

antidepressant drugs, categorized by gender and age. Height of each bar
represents the percentage of total,

male and female

patients

receiving

antidepressant prescriptions in three age categories from the sample population
of people eligible for Montana MedicAid.

The data demonstrate expected

differences in gender specific antidepressant therapy based on previous
literature data demonstrating a higher percentage of women with clinically
diagnosed depression than men.

However, although literature predicts older

patients will be clinically diagnosed with depression at a higher rate than
younger individuals, the present results demonstrate that women and men in the
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21-64 age group show as high an Incidence of antidepressant prescriptions as
the ages 65+.
Number of Antidepressant Recipients

B Female
Male
"5. 1000
«

800

0
Age

Figure

12:

Num ber

of

1996

Montana

MedicAid

recipients

receiving

antidepressant drugs, categorized by gender and age. Height of each bar
represents the number of total, male and female antidepressants recipients of
Montana MedicAid further segregated by age.
This breakdown demonstrates that the largest number of people receiving
antidepressant prescriptions In this survey population is associated with women
in child-bearing years (21-40).
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Protein Standard
Bradford Assay
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1.10
1.05
0.99
0.94
0.88
0.83
0.77
0.72
0.66
0.61
0.55
0.50
0.44
0.39
0.33
0.28
0.22
0.17
0.11
0.06
0.00
0

1 2

3 4
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6 7

8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
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Figure 13: Standard Curve o f pure protein concentration created with BSA.
The lines are representative of the reading on a spectrometer at OD 595
wavelength with various known amounts of BSA in a Bradford dye.

Chapter 4
Discussion
Osmotic Pump Experiment
Chronic spironolactone reduced rat total 24-hour locomotor activity, most
noticibly during the active hours, which for rats is during the dark phase (19:007:00 hours). This provides evidence that 1) MR are linked to locomotor activity
and potentially to depression and 2) are important when CO RT levels, and
subsequently GR activation are believed to be highest.

The manner by which

this linkage is manifested was unexpected from the action of brain M R proposed
in the literature.
Meijer and de Kloet proposed that a continuous decrease in limbic GR
and a high ratio of activated MR to GR in the hippocampus are involved with
depression by reducing brain serotonin, hippocampal serotonin’s 1A receptor (5HTia), and attenuating 5-HTia neuronal hypopolarization.^°® The effect of stress
to increase In the activity of the rate limiting enzyme of serotonin synthesis,
tryptophan hydroxylase is blocked by central administration of a GR antagonist.
107

108

109

activation and circulating CO RT appear to both enhance

tryptophan hydroxylase expression and neuronal serotonin release (capacity).
111

112

Therefore, decrease in brain GR could decrease serotonin synaptic

release, which has been theorized to be associated with depression
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5-HTia agonists have many central effects and some 5-HTia agonists are
used as antidepressants and anxiolytics, such as buspirone, ipsapirone and
flesinoxan/^^

This

G-protein

coupled

serotonin

receptor,

physiologically influenced by MR in at least two manners.
decreases the protein expression of S-HT ia .^^"*

5-HTia,

is

MR activation

In electrophysiological

experiments of hippocampal neurons which co-express MR, GR and 5-HTia, an
M R agonist attenuates the neuronal response (hypopotarization) to serotonin
and 8 - 0 H DPAT (a specific 5-HTia a g o n i s t ) . T h e MR agonist effect is
removed by co-administration of a GR agonist. Therefore, serotonin’s effects on
these 5-HTia receptors would be most influential during physiological states of
high CORT and least influential at low CO RT or low GR activation, but not
complete CO RT removal. Electrophysiological effects have been observed to be
decreased with both short-term and long-term administration of low CO RT to the
hippocampal neurons.
In the Meijer and de Kloet model, low GR would result in a decrease in
serotonin production by the raphe nuclei and dexamethasone would fail to
suppress CO RT by binding to hypothalamic GR. The high hippocampal MR/GR
ratio would attenuate 5-H T ia hypopolarization of neurons and decrease 5-H T ia
expression. These effects, they theorize, would contribute to depression.
The present results, that an MR antagonist decreases locomotor activity,
do not contradict that low GR could be involved in depression, but they provide
evidence that low M R might also be involved. Continuous administration of
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spironolactone into the brain would have been expected to decrease the MR to
GR ratio, increasing 5-H T ia protein expression and hypopolarization effect.
These predicted effects were thought not to induce depression-like behavior,
such as low total 24-hour locomotor a c t i v i t y . H o w e v e r , spironolactone lowered
activity during the dark (active) hours, when GR activation should be high and
thus, high hippocampal GR/MR ratio. The neurochemical systems involved in
this lowering of locomotor activity are unknown, but, hippocampal 5-HTia is an
unlikely candidate.

Although, 5-HTia has effects on locomotor activity most

literature reviewed (from a Medline search of abstracts) implied this effect is from
the 5-HTia in the suprachiasmatic nucleus and the raphe nuclei, while serotonin
5-HTib receptors, catecholaminergic receptors and other receptors are involved
in locomotor activity at the hippocampus.
The depression-like effects of both MR and GR provides for an alternative
hypothesis to be proposed. Both the activated MR and the activated GR bind to
the same sequences of DMA response elements (GRE) and to individual
response elements, MRE and GRE.

Activated hippocampal M R or GR are

found co-localized in some nuclei compartments and not co-localized in other
nuclear c o m p a r t m e n t s . T h e dimerization of steroid receptors is thought to be
necessary for steroid/transcription interactions to occur.

This dimerization

occurs after one activated receptor has already bound to the proper GRE.^^^
Both homodimers and heterodimers can occur with MR and GR respectively/^
It is quite feasible, that DNA response elements could exist for GR+GR, M R+M R
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and M R+G R dimers or that one receptor of the dimer could be replaced by
another, making a homodimer into a heterodimer.

In normal physiological

conditions CO RT binding GR fluctuates from 5% to 90% with the circadian level
of available CORT, while almost all MR are thought to be bound and activated.
In this condition, the binding and activation of GR would be the limiting factor for
the M R+G R heterodimer.

By pharmacologically lowering MR binding by

interactions with spironolactone, the M R+GR heterodimer would also be
decreased like it is in circumstances of low CORT and low GR activation, except
now the availability of MR is the limiting factor.

Therefore, the M R+GR

heterodimer would be decreased by low MR or low GR. Perhaps, this MR+GR
heterodimer is involved in clinical depression.
Another possible explanation might be that MR+MR homodimer alters the
expression of a protein and this alteratrion of the protein would be necessary in
order for GR+GR alterations of a separate protein(s) to occur. Therefore, either
low MR or low GR activation would be involved in depression. Similar to what
was observed in low activated brain M R In rats, adrenalectomized (ADX) rats
(when neither MR nor GR are activated) demonstrated a decrease in total 24hour wheel running activity, but no change in the circadian rhythm of activity.^^^
Explorative

behavior

of

treatment

animals

(including

vehicle)

all

decreased from before treatment values, but there was no difference between
treatment groups.

In addition, the animals did not appear sickly nor was there

difference in body weight in any of the treatment groups (data not shown).
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Therefore, it is unlikely the differences in total 24-hour locomotor activity are
from an effect other than spironolactone treatment.
If both MR and GR are necessary for GR to have effects on the
serotonergic system, then the half of the hypothesis described by Meijer and de
Kloet would be correct. Low GR activation results in low serotonin synthesis and
release contributing to depression.

However, there may need to be MR

activation In order for GR to exert a definitively full effect on locomotor activity
and on moods.

Activated dim er
Serotonin
Locomotor Activity
CO RT regulation
Mood

low or no MR+GR
low
low or none
poor
depressed/sleep

mid MR+GR
mid
mid
average
mid

high MR+GR
high
high
?
manic

Table 6: Proposed relationship between activated MR+GR level, locom otor
activity, serotonergic activity, CORT regulation and mood.

This change in activity and possibly serotonin levels, indicates that both
the MR and GR might be involved in the etiology of depression.

Animals

receiving acute brain Injections of MR antagonists exhibit "depression-like”
behaviors.

128 129 130

Activated hippocampal MR directly and independent of GR

suppress 5-H T ia expression.

118 131

A high number of 5-HT ia (Implying low MR)

are seen in patients who suffer from depressive disorders and in people who
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have committed suicide by non-violent means/^^ These high levels of 5 -H T ia
could have resulted from low MR (hippocampal 5 -H T ia ).
to be involved in the regulation of plasma CORT.

^

Brain MR are thought
Low brain M R would

cause a lack of CO RT regulation in a similar manner to that seen in depression.
Antidepressants cause an increase in hippocampal MR in a time course similar
to their therapeutic effects.

es ee e? es es 70

Q R

and MR are reduced with

chronic immobilization (learned helplessness) and similar chronic stresses, while
5 -H T ia receptors increase.

Thus, low brain MR activation may well be

involved in the etiology of certain types of depression.
However, only one patient case has been reported of spironolactone
being associated with depression.^^

Of note, lethargy (decreased locomotor

activity) is a side effect of spironolactone diuretic t h e r a p y . I n t e r e s t i n g l y ,
spironolactone has been successful as a substitute of lithium in bipolar disorder
p a t i e n t s . H o w e v e r , the pharmacological dose administered directly into the
brain to rats in this experiment were at a much greater concentration in the brain
than a pharmacotherapeutic dose administered orally to people.

This might

explain, the lack of complaints of depression in people taking spironolactone.
Another explanation is that MR antagonists do produce lethargy, but not lethargy
associated with depression.
That the MR agonist, aldosterone, did not alter locomotor activity at all, is
not a surprise, because a high percentage of M R are always bound, so adding
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an exogenous ligand to an already at least 80% activated receptor might have
little net effect.
Hippocampal MR were predicted to be involved with regulation of CO RT
levels, for it had been shown that acute administration of MR agonists decreased
C O R T and M R antagonists Increased CORT.^®

^ However, in the present

study there was no change in plasma CORT between any treatment groups.
The effects of the drug treatments could have been masked by stress of being in
a new environment,

resulting

in high CORT

levels.

However,

several

precautions were taken to minimize this possibility. Animals were brought up in
their home cages several hours before the experimentation.

Cannula were

connected to collecting tubes at least one hour prior to removal of the first blood
sample, and many precautions were taken to assure stable, quiet lab conditions
during the course of the experiments.

Another possibility is that the brain

adjusted to the chronic drug treatments and thereby normalized CO RT levels. A
similar chronic study of manipulating brain MR by continuous infusion of MR
antisense (MRAS) also had no effect on CORT levels.®^
The ability to remove stress free blood samples during dark hours would
have been beneficial, since CO RT plasma levels fluctuate in a circadian rhythm
with higher levels occurring during dark hours.

This is especially true since,

spironolactone effects on locomotor activity were noticeable only during the dark
hours.

However, it was very difficult to obtain a plasma sample during the

nocturnal hours from rats under red light.

W hen obtained, often some
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manipulation of the animals had to be performed introducing a potential for
stress and altered CORT levels.
In the future, a study should be conducted on CORT levels after a
dexamethasone bolus to see if CO RT regulation is altered by the low activated
M R In the brain.

1995 Survey of Montana MedicAid Antidepressant Recipients
The 1995 survey of Montana MedicAid patients showed at least three
times more women received anti-depressant therapy versus men and that
women in their child bearing years represented by far the largest antidepressant
prescription

recipients.

The

higher

incidence

of women

diagnosed

with

depression compared to men has been previously reported and might be
influenced by estrogen and/or progesterone levels. A large change in plasma
estrogen or progesterone concentrations has been associated with clinical
depression; Including the dramatic decrease which occurs in estrogen and
progesterone after child birth or menopause, or the increase in estrogen and
progesterone which can result from drug contraceptive therapy.® ^ ® It is possible
that the highest frequency of recipients of an antidepressant prescription
(women between the ages 21-40) corresponds also with the highest use of drug
contraceptives.

The analysis utilized could not show recipients of concurrent

prescriptions, such as oral contraceptives and antidepressants, which would
have been interesting considering the highest number of prescriptions for drug
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contraceptives occur In the age group of the highest number of antidepressant
prescriptions.
Interactions between gonadal hormones and CORT and CORT receptors
do o c c u r . F e m a l e s

(both human and animal) are known to have

higher basal CORT, as well as larger responses to stress and immune
challenges than males/'*^

The level of CORT and CORT sensitivity to

various stressors fluctuates with the menstrual cycle.^"*® Progesterone is a very
strong MR antagonist in vitro, with a higher affinity than spironolactone and in
vivo (but estrogen appears to need to be present for this effect, implying
progesterone in vivo effects on MR may not be directly at the M R binding
domain).^^^

Either spironolactone or progesterone have been successful

prophylactic therapeutics of pre-menstrual syndrome (RMS), this suggests that
hippocampal M R activation or MR+GR activation might be too high in RMS.
One should keep in mind that the survey includes primarily people with
low income.

Certainly, some of the women in child bearing years are single

mothers. Since a large percentage of these women are probably receiving birth
control, perhaps the oral contraceptives are a factor In the depression. Another
possibility is that antidepressant drugs are the latest "Mother's Littie Helper*', a
Brave New World soma, which removes emotions to help mothers with the
stress of raising children.

In this sense, the antidepressants may also be

overprescribed in these age groups. This brings up some serious social Issues
about Montana, if many of our mothers are on antidepressants.
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Monoclonal MR Antibody Specific to the Ligand-Binding Site Experiment
The monoclonal antibody specifically raised to the ligand-binding site of
the peripheral M R in the kidney, did not bind to hippocampal MR in the present
study, either by western blot or immunocytochemistry (ICC) analysis.

The ICC

detection of hippocampal MR could have been potentially masked by the ligand,
because most MR are thought to be ligand bound. However, the tissue samples
in the western blot analysis were boiled for two to three minutes, incubated with
a powerful detergent and moved through a gel by a high power electrical circuit.
By definition and from these conditions, all the proteins in a western blot are
thought to be denatured. It is unlikely, that such a denatured protein would still
be masked by a ligand. In order, to make sure that the lack of M R binding was
not from low protein concentration, up to 300 pg total protein of a tissue sample
had been placed in a well.

The hippocampal tissue GR was detected in an

identical procedure, using a polyclonal antibody to GR.

Currently, no such

polyclonal antibody commercially exists for brain MR analysis.
Therefore, the most likely conclusion from the present MR results is that
ligand binding site of MR in the hippocampus is not the same amino acid
composition as the ligand binding site of MR in the kidney. The difference in the
ligand-binding domain of MR could represent a difference in active versus
inactive MR, or it could truly represent a difference in hippocampal versus
kidney MR.

Splice variants of MR have been found in the hippocampus.^^®
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Certain fragments of activated,
proteolysis/^^

but not inactivated MR are

resistant to

This indicates that a structural change occurs in M R upon

ligand activation. Earlier studies have suggested that there is a slight variation
between the hippocampal and kidney MR, which might allow for the ligand
specificity of the t i s s u e s . N o n - p e p t i d e post-translational modifications
could also explain the various observed difference between

kidney and

hippocampal MR, such as sugar or lipid additions or deletions.
In the future, a study should be conducted on the binding of the
monoclonal antibody in chronically adenalectomized rats. This would allow the
hippocampal MR to assume an unbound inactive form. If there still is no binding
by the monoclonal antibody to these MR, then the only remaining possibility is
that brain MR are distinct from peripheral MR.
Since, spironolactone has been successfully used in the treatment of bi
polar disorder and pre-menstrual syndrome and that lithium has MR antagonist
like qualities, then high MR+MR homodimer or high MR+GR heterodimer or
both, might be involved with manic-like moods.

The low brain GR theory of

depression, coupled with the decrease of locomotor activity in these experiments
suggest that low M R+G R heterodimer might be involved in depression.

Novel

drugs which enhance activated MR+GR in a time course faster than present
therapeutics may represent future antidepressants. The lack of a monoclonal
antibody bound to the ligand binding site of hippocampal tissue, but functional
binding to MR In renal tissue, suggests the ligand-binding site might be different.
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Since, spironolactone has successfully been used as a mood stabilizer, perhaps
to high M R+G R are involved with bi-polar disorder.

Future mood stabilizers

might make use of the binding-site difference to specifically block brain MR.

Summary
1. The chronic brain administration of a MR antagonist lowered total 24-hour
locomotor activity suggesting that the brain MR may be involved in the etiology
of behaviors associated with depression.

2. A survey of people eligible for Montana MedicAid in 1995 found three times
more women received antidepressants than men and the largest group of
recipients was women between the ages 20 to 40 years.

Whether this was

correlated to oral contraceptives or other gonadal hormone factors was not
discernible in the present analysis.

3. Hippocampal MR were not detectable with a monoclonal antibody specific to
the peripheral ligand binding site, while kidney M R were detected. This was true
for both western blot and ICC analysis. The data suggest that two different MR
proteins

exist,

either

expression/ alteration.

from

post-activation

alterations

or

pre-activation
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